We will continue to provide comprehensive analysis and reports about therapeutic antibody licensing deals between Chinese biopharma and overseas companies. In this third business report on this topic, we focus on licensing deals closed in 2022.
Read StoryFourty antibody deals were closed at a total value of ~ $14.7 billion in 2021. Twenty two of them were in-licensing deals; eighteen were out-licensing deals.
Read StoryWe are excited to announce that PharmaDJ and the Chinese Antibody Society will collaborate to provide comprehensive analysis and reports about therapeutic antibody licensing deals between Chinese biopharma and overseas companies.
Read Story